Drug to Target PD L1 and CD137 for Solid Tumors is under clinical development by Les Laboratoires Servier and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Drug to Target PD L1 and CD137 for Solid Tumors’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Drug to Target PD L1 and CD137 for Solid Tumors overview
The drug candidate is under development for the treatment of solid tumors. It acts by targeting PDL 1 and 4-1BB.
Les Laboratoires Servier overview
Les Laboratoires Servier (Servier) researches, develops, manufactures, and markets drugs for treating various diseases. The company’s portfolio of marketed products treats central nervous system (CNS) disorders, cardiovascular diseases, cancer, ENT disorders, respiratory diseases, hematological disorders, hormonal disorders, and others. The company also provides generic drugs and contract development and manufacturing services across its global network. It invests a substantial amount of revenue in R&D, particularly in France and Hungary. The company also provides digital therapeutic solutions through its e-health division, WeHealth Digital Medicine. It sells products in Europe, America, Middle East, Africa, and Asia. Servier headquartered in Suresnes, France
For a complete picture of Drug to Target PD L1 and CD137 for Solid Tumors’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
